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InvasionChronic stress accelerates metastasis – the main cause of death in cancer patients – through the activa-
tion of b-adrenoceptors (bARs). We have previously shown that b2AR signaling in MDA-MB-231HM breast
cancer cells, facilitates invadopodia formation and invasion in vitro. However, in the tumor microenviron-
ment where many stromal cells also express bAR, the role of b2AR signaling in tumor cells in metastasis is
unclear. Therefore, to investigate the contribution of b2AR signaling in tumor cells to metastasis in vivo,
we used RNA interference to generate MDA-MB-231HM breast cancer cells that are deficient in b2AR. b2AR
knockdown in tumor cells reduced the proportion of cells with a mesenchymal-like morphology and, as
expected, reduced tumor cell invasion in vitro. Conversely, overexpression of b2AR in low metastatic MCF-7
breast cancer cells induced an invasive phenotype. Importantly, we found that knockdown of b2AR in
tumor cells significantly reduced the impact of stress on metastasis in vivo. These findings highlight a cru-
cial role for b2AR tumor cell signaling in the adverse effects of stress on metastasis, and indicate that it
may be necessary to block b2AR on tumor cells to fully control metastatic progression.
 2016 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Despite advances in cancer treatment, metastasis remains the
greatest clinical challenge in the management of cancer and con-
tributes to the majority of deaths in cancer patients (Mehlen and
Puisieux, 2006). Studies have revealed that chronic stress drives
cancer progression by accelerating metastasis in in vivo mouse
models of various cancer types (Ben-Eliyahu et al., 2000;
Campbell et al., 2012; Kim-Fuchs et al., 2014; Lamkin et al.,
2015; Le et al., 2016; Liu et al., 2015; Sloan et al., 2010; Thaker
et al., 2006; Zhao et al., 2015). This raises the possibility that tar-
geting stress responsive signaling may help slow cancer progres-
sion and metastatic dissemination (Sloan et al., 2010; Thaker
et al., 2006), and provide a much needed additional therapy for
the treatment of cancer.
The sympathetic nervous system (SNS) plays an important role
in the response to stress, which triggers the release of cate-
cholaminergic neurotransmitters from SNS nerve fibers (Elenkov
et al., 2000). These neurotransmitters activate b-adrenoceptors(bARs), which induces downstream signaling in responsive cells
and leads to transcriptional changes (Elenkov et al., 2000). A num-
ber of different cell types present within the tumor microenviron-
ment express bARs, and thus are able to respond to stress signaling.
These include immune cells and endothelial cells (Abrass et al.,
1985; Graf et al., 1993; Sanders et al., 1997), which have a critical
role in driving cancer progression (Condeelis and Pollard, 2006;
Folkman, 2002; Le et al., 2016). In response to stress, stromal cells
contribute to metastasis by remodeling tumor architecture in ways
that favor dissemination of tumor cells. This includes macrophage
recruitment into the primary tumor (Sloan et al., 2010; Zhao et al.,
2015) and vascular remodeling to increase blood vessel (Sloan
et al., 2010; Thaker et al., 2006) and lymph vessel (Le et al.,
2016) routes of tumor cell dissemination. Experimental strategies
that prevent either macrophage recruitment or vascular remodel-
ing block stress-enhanced metastasis (Le et al., 2016; Sloan et al.,
2010; Thaker et al., 2006), demonstrating that regulation of the
tumor stroma plays an important role in the effects of stress on
cancer progression.
Tumor cells also express bARs (Pon et al., 2016; Reeder et al.,
2015), and activation of bAR signaling increases invasion of tumor
cells, as measured by in vitro assays (Creed et al., 2015; Kim-Fuchs
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cultures (Creed et al., 2015). Previously, we discovered that the
b2AR-selective agonist formoterol, but not the b1AR-selective ago-
nist xamoterol, induced the formation of invadopodia in breast
cancer cells (Creed et al., 2015). Invadopodia are actin-rich cellular
structures that localize matrix metalloproteases (MMPs) and
degrade the extracellular matrix for tumor cell invasion (Murphy
and Courtneidge, 2011). However, the role of b2AR-regulated inva-
sion in vivo is less clear. Unlike in simple in vitro assays, in the
tumor microenvironment contextual cues provided by stromal
cells influence whether tumor cells are able to escape the primary
tumor and disseminate to distant tissues (Bissell and Labarge,
2005; Devaud et al., 2014). Therefore, in the complex tumor
microenvironment where stromal cells also respond to bAR stress
signaling, it is unclear whether b2AR signaling in tumor cells signif-
icantly contributes to metastasis. Previous studies that used sys-
temic b-blockade to investigate bAR regulation of metastasis
were unable to distinguish the contribution of bAR signaling in
tumor cells, as systemic b-blockade indiscriminately targets both
tumor cells and stromal cells (Campbell et al., 2012; Sloan et al.,
2010; Thaker et al., 2006). While use of siRNA has shown that
b2AR signaling affects the growth of tumor cells injected directly
into metastatic target organs (Thaker et al., 2006), it is not known
if signaling from b2ARs on tumor cells is required for the early
stages of the metastatic cascade including tumor cell invasion
and escape from the primary tumor.
To address this, we used an shRNA approach to generate breast
cancer cells that were stably deficient in b2AR. Using MDA-MB-
231HM cells, a human breast cancer cell line that is highly respon-
sive to bAR signaling, we investigated the effect of tumor cell b2AR
knockdown on metastasis from a primary orthotopic mammary
tumor. Consistent with previous pharmacologic studies, genetic
modulation of MDA-MB-231HM b2AR reduced cell invasion, and
prevented a shift to mesenchymal cell morphology. Conversely,
upregulating b2AR expression in MCF-7 tumor cells with low
endogenous b2AR expression increased invadopodia formation,
demonstrating a central role for b2AR in regulating tumor cell inva-
sion. Furthermore, we show that b2AR modulation in MDA-MB-
231HM tumor cells attenuated stress-enhanced metastasis from
primary mammary tumors. These findings show that in this model
of breast cancer, b2AR-driven tumor cell invasion plays a signifi-
cant role in the effects of stress on metastasis. These findings sug-
gest that pharmacological strategies that block the effects of stress
on metastasis may need to also target b2AR on tumor cells to fully
control metastatic progression.2. Methods
2.1. Genetic manipulation of tumor cell b2AR expression
The human breast cancer cell line MDA-MB-231HM (a kind gift
from Dr. Zhou Ou, Fudan University Shanghai Cancer Center,
China) (Chang et al., 2008) was transduced with a lentiviral vector
containing codon optimized firefly luciferase under the control of
the ubiquitin-C promoter as previously described (Le et al.,
2016). The identity of the cell line was confirmed by karyotyping
(CellBank Australia). Cells were maintained in DMEM (Invitrogen,
USA) supplemented with 200 mM glutamine and 10% fetal bovine
serum (FBS; Life Technologies, USA) at 37 C with 5% CO2. To
silence ADRB2, cells were transduced with shRNA that specifically
targets human ADRB2 (shADRB2a: 50-TGCTGTGACTTCTTCACGA-30;
shADRB2b: 50-GCCATCAACTGCTATGCCA-30) or scramble control
sequence (SCR): 50-ATCTCGCTTGGGCGAGAGTAAG-30 (Dharmacon,
USA). MCF-7 cells were acquired from ATCC (Manassas, Virginia)
and grown in MEM supplemented with 200 mM glutamine and10% FBS. The b2AR-GFP construct was made by sub-cloning the
human b2AR coding sequence 50 to a codon-humanized GFP gene
derived from the vector pGFP2-N1 (Perkin Elmer), and sequence
verified. Cells were stably transduced and GFP-positive cells sorted
by FACS. All experiments used bulk cell populations to avoid clonal
effects. Cells were confirmed negative for mycoplasma using
MycoAlertTM Mycoplasma Detection Kit (Lonza, Australia).
2.2. Functional analysis of b2AR knockdown in tumor cells by cAMP
accumulation assay
Tumor cells (4  104) were seeded into a 96-well plate and
serum-starved overnight. Cells were then washed and incubated
in pre-warmed stimulation buffer (140 mM NaCl, 5 mM KCl,
800 nM MgSO4, 200 nM Na2HPO4, 440 nM KH2PO4, 5 mM HEPES,
1.3 mM CaCl2, 5.6 mM glucose, 0.1% w/v BSA, 500 lM 3-isobutyl-
1-methylxanthine, pH 7.4) at 37 C in 0% CO2 for 30 min.
Formoterol hemifumarate (b2AR-selective agonist; Tocris, UK) at
indicated concentrations was then added for 10 min before cells
were lysed with ice-cold 100% ethanol, evaporated and rehydrated
with 50 lL detection buffer (0.1% BSA, 5 mMHEPES, 0.3% Tween20,
pH 7.4). cAMP in cell lysates (5 lL) was then incubated with 1 unit
of AlphaScreenTM acceptor beads (Perkin Elmer, USA) diluted in
detection buffer, followed by incubation with 1 unit of donor
beads. Fluorescence signal was measured using a Fusion plate
reader (Perkin Elmer, USA). cAMP accumulation was expressed as
pmol/well.
2.3. Tumor cell proliferation
Tumor cells (5  104) were seeded into a 12 well plate and
serum-starved overnight. Cells were then treated with 1 lM iso-
proterenol (non-selective b-agonist Sigma, USA) in vehicle (DMEM
supplemented with 2% FBS). Isoproterenol was replenished every
24 h. Cell numbers were quantified using the TaliTM Image-Based
Cytometer (Invitrogen, USA) at indicated time points.
2.4. Cell morphology assay
Tumor cells (5  103) were seeded into a 96 well plate and
serum-starved overnight. Cells were then treated with or without
1 lM isoproterenol in the absence or presence of ICI-118,551
(b2AR-selective antagonist, 1 lM, Tocris, UK) in DMEM supple-
mented with 2% FBS. Isoproterenol and ICI-118,551 were replaced
every 24 h to minimize possible effects of auto-oxidation. Cells
were imaged using a 20x long WD objective every 24 h for 3 days
using the Operetta High-Content Imaging System (Perkin Elmer,
USA). At each time point, nine random fields of view from each
well were captured and analyzed using Harmony High Content
Imaging and Analysis Software (version 3.5, Perkin Elmer). The
roundness of individual cells was assessed using the proprietary
analytical tools provided in the Harmony Analysis software. The
cell roundness parameter ranged between 0 and 1 where a value
of 1 is equivalent to perfect roundness. The parameter threshold
to define a mesenchymal-like cell was set at 0.5 (Ren et al.,
2015; Yang and Weinberg, 2008). The proportion of
mesenchymal-like tumor cells in the population meeting this crite-
rion was then quantified.
2.5. Invadopodia assay
Gelatin was labeled with Alexa Fluor-568 protein labeling kit
according to the manufacturer instructions (Life Technologies,
USA). Culture vessels were coated with an 8:1 ratio of unlabeled
to labeled 0.2% gelatin and topped with a thin layer of unlabeled
10 lg/mL human fibronectin to promote cell adherence.
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were then seeded onto the prepared cultured vessels containing
10% serum, ±bAR agonists (0.5 lM isoproterenol or 0.5 lM for-
moterol hemifumarate) for 5 h. Cells were then fixed in 4%
paraformaldehyde, actin stained with phalloidin and nuclei coun-
terstained with 1 lg/ml Hoechst 33242. Invadopodia were imaged
on a Leica SP8 Confocal using a 63x PL APO CS2 1.4NA objective.
Images were captured through LAS AF software version 3.2 (Leica
Microsystems, North Ryde Australia). Images were prepared as Tiff
stacks for actin and gelatin using ImageJ and submitted to the
Invadopodia Analysis Server (IAS) and analyzed as previously
described (Creed et al., 2015).
2.6. Gene expression analysis
Tumor cells (7  105) were seeded into a 6 well plate and
serum-starved overnight before treatment with vehicle, isopro-
terenol (1 lM), and/or ICI-118,551 (b2AR-selective antagonist,
1 lM) in DMEM supplemented with 2% FBS for the time indicated,
prior to analysis. Total RNA was isolated using RNeasy Mini Kit
(Qiagen, Germany). qRT-PCR was used to quantify gene expression
in 100 ng of total RNA using Taqman probes (Applied Biosystems,
USA) targeting human bAR subtypes (ADRB1 Hs02330048_s1,
ADRB2 Hs00240532_s1, ADRB3 Hs00609046_m1) and MMP2
(MMP2 Hs01548727_m1) and iScript One-Step RT-PCR kit (Biorad,
USA) with 50 PCR amplification cycles of 15 s of strand separation
at 95 C and 30 s of annealing and extension at 60 C. Transcript
levels for genes of interest were normalized relative to scramble
control cells.
2.7. Tumor cell invasion assay
Serum-starved tumor cells (1.5  105) were suspended in
300 lL DMEM supplemented with 2% FBS with or without 1 lM
isoproterenol and seeded into Transwell chambers (8 lm pores,
PET membrane, Sigma, USA) that were pre-coated with 100 lL
Matrigel (2 mg/mL, BD, USA). For 24 h, cells were allowed to invade
toward the bottom chamber, which was filled with media supple-
mented with 10% FBS with or without 1 lM isoproterenol. Mem-
branes were then fixed with 4% paraformaldehyde (Sigma, USA)
and stained with Hoechst 33342 (1:1000, Sigma, USA) and imaged
using a Nikon Ti-E microscope, fitted with 10x Plan Apo 0.3NA
objective and a Photometrics CoolSNAP Myo camera. Fluorescent
excitation and emission was provided by a Nikon UV-A filter cube
(excitation 355/50 and emission 420LP). Images were captured
using NIS Elements software (version 4.3, Nikon Instruments).
Invaded cells were counted using the Fiji distribution of ImageJ
(Schindelin et al., 2012).
2.8. Breast cancer model with restraint stress
To investigate spontaneous metastasis from an orthotopic pri-
mary tumor, 2  105 tumor cells in 20 lL PBS (Invitrogen, USA)
were injected into the left 4th mammary fat pad of anesthetized
(3% isoflurane) 8 week-old female BALB/c nu/nu mice (University
of Adelaide, Australia). Mice were housed under PC2 barrier condi-
tions (temperature and humidity controlled, 12 h dark/light cycle)
and acclimatized in a home cage for a week prior to tumor cell
inoculation. Primary tumors were monitored by digital caliper
twice a week and volume calculated using the formula:
(length width2)/2. Mice were randomly assigned to either stress
or non-stress group (n = 5 per group). To induce chronic stress,
mice were subjected to a well-characterized restraint stress para-
digm (Sloan et al., 2010; Le et al., 2016; Thaker et al., 2006). Mice
were placed in a ventilated Perspex chamber that restricted move-
ment for 2 h per day for a total of 21 days, commencing 7 daysbefore tumor cell injection. Mice in the non-stress group remained
in their home cage throughout the 2 h period. Distant metastasis to
lymph nodes and lung was monitored longitudinally twice weekly
using bioluminescence imaging, which allows repeated measure
analysis of metastatic burden in the same mouse throughout the
experiment. Mice were injected with D-luciferin (150 mg/kg,
CHOICE Analytical) via tail vein and imaged using an IVIS Lumina
II (Perkin Elmer) (Le et al., 2016; Sloan et al., 2010). Mice were
euthanized 28 days after tumor cell injection and tissue-specific
metastasis was confirmed in lung and axillary lymph node by
ex vivo bioluminescence imaging. In vivo experiments were con-
ducted in duplicate. All procedures involving mice were carried
out under protocols approved by the Institutional Animal Ethics
Committee and in accordance with National Health and Medical
Research Council animal ethics guidelines.2.9. Statistical analysis
Longitudinal mixed-effect linear models were used to deter-
mine the effect of stress on the trajectory of metastasis, and to
evaluate if those effects were modified by tumor b2AR knockdown
(Verbeke and Molenberghs, 2009). We examined the stress x treat-
ment (tumor cell b2AR knockdown) interaction in a 2 (non-stress
vs. stress)  3 (scramble control vs. shADRB2a vs. shADRB2b)
experimental design. Data were analyzed according to the model
Yijt = b1di1tij + b2di2tij + b3di3tij + b4di4tij + b5di5tij + b6di6tij + eij, where:
Yijt are mouse-specific and day-specific primary tumor volume or
luciferase signals (Fig. 4a) for the ith mouse on the logarithmic
scale; tij is the time (days of follow up), dij (j = 1,. . .,6) are binary
variables so that dij = 1 if the ith mouse belongs to the jth group
and 0 otherwise; eij is the random error term. Linear models were
fitted using the routine lm while multiple comparisons used the
routine glht in the package multicomp (Bretz et al., 2010). The
effect of stress on the trajectory of metastasis or primary tumor
volume was calculated using the difference in gradient of fitted
lines between stress and non-stress conditions for each tumor cell
type. Pearson’s correlation analysis was performed to assess the
relationship between the effect of stress on the trajectory of pri-
mary tumor volume and the effect of stress on the trajectory of
metastasis. For ADRB expression in MCF7-WT andMCF7-b2AR cells,
unpaired t-tests were used to compare each bAR subtype between
the two cell lines. For cell proliferation and cell morphology assays,
the effect of isoproterenol on cell proliferation or mesenchymal-
like morphology of each cell lines was compared using one-way
ANOVA repeated measures followed post hoc Tukey’s planned com-
parison tests when applicable. For all other experiments, a two-
way ANOVA test was first performed to identify the presence of
interaction between treatments. Post hoc Tukey’s planned compar-
ison tests were performed when applicable, to test the simultane-
ous differences between pairs of treatment effects on experimental
responses (MMP2 gene expression, in vitro invasion, number of
invadopodia, ex vivo bioluminescence signals and primary tumor
mass). Experiments were repeated 2–4 times. Treatment effects
showing p-values smaller than 0.05 were regarded as statistically
significant. Statistical analyses were carried out in both R comput-
ing environment (Team, 2014) and Prism 6 software (GraphPad
Software, La Jolla, CA, USA).3. Results
3.1. Generation of MDA-MB-231HM cells deficient in b2AR
We have previously shown that b2AR is the only functional bAR
subtype in MDA-MB-231HM cells (Pon et al., 2016). Therefore, we
used two different hairpin sequences that target the gene encoding
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Fig. 1. Generation of MDA-MB-231HM breast cancer cells deficient in b2AR. (a)
Quantification of ADRB mRNA transcript levels using qRT-PCR in MDA-MB-231HM
cells transduced with shRNA scramble sequence (control) or shRNA targeting
ADRB2 (shADRB2a and shADRB2b) (n = 4). ND: not detected. (b) Quantification of
cAMP accumulation in scramble control, shADRB2a and shADRB2b tumor cells in
response to increasing concentrations of the b2AR selective-agonist formoterol
(n = 3). (c) Proliferation of control, shADRB2a and shADRB2b tumor cells (n = 3).
Data represent mean ± standard error. ⁄⁄p < 0.01 by one-way ANOVA with post hoc
Tukey’s planned comparison tests.
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231HM breast cancer cells, and generated shADRB2a and shADRB2b
cell lines. To examine the efficiency of ADRB2 silencing, we usedqRT-PCR to quantify the expression of ADRB2 in shADRB2a and
shADRB2b cells relative to control cells transduced with a scram-
bled shRNA sequence (scramble control). ADRB2 expression was
reduced by >50% in both shADRB2a and shADRB2b cells compared
to scramble control cells (p < 0.01) (Fig. 1a). ADRB1 expression was
not affected by shRNA transduction, and ADRB3 expression was not
detected in these cell lines (Fig. 1a), consistent with our previous
findings (Creed et al., 2015; Pon et al., 2016). Stable knockdown
was confirmed with reduction of the ADRB2 transcript maintained
even after 6 weeks in culture (data not shown).
To investigate the effect of ADRB2 knockdown on receptor func-
tion, we evaluated cAMP accumulation as an indicator of receptor
signaling. Cells were stimulated with the b2AR-selective agonist
formoterol, which induced cAMP accumulation in scramble control
cells (Emax = 0.29 ± 0.06 pmol/well) (Fig. 1b). However, the cAMP
response was blunted in b2AR-deficient cell lines (shADRB2a:
Emax = 0.13 ± 0.02 pmol/well; shADRB2b: Emax = 0.21 ± 0.04 pmol/
well) (Fig. 1b). Reduction of the cAMP response in b2AR-deficient
cell lines was also demonstrated by a need for a greater concentra-
tion of formoterol to reach the EC50 (50% of the maximal response,
control cells: 13.30 ± 9.25 nM vs. shADRB2a: 63.94 ± 38.67 nM;
shADRB2b: 32.58 ± 13.21 nM) (Fig. 1b).
To determine if ADRB2 knockdown affected tumor cell prolifer-
ation, we compared the in vitro proliferative activity of b2AR-
deficient cells to scramble control cells. b2AR knockdown did not
modulate the proliferation of tumor cells, either under baseline
conditions (Fig. 1c), or after treatment with the non-selective
bAR agonist isoproterenol (Supplementary Fig. 1). Collectively,
these findings confirmed the generation of MDA-MB-231HM tumor
cell lines with reduced levels of ADRB2 transcription, blunted b2AR
signaling, and without compromised tumor cell proliferative
capability.
3.2. Characterization of tumor cell invasiveness in MDA-MB-231HM
cells deficient in b2AR
Our previous studies using pharmacological modulation of b2AR
found a crucial role for tumor cell b2AR signaling in promoting
invadopodia formation and tumor cell invasion (Creed et al.,
2015; Pon et al., 2016). To examine if genetic knockdown of b2AR
similarly affected tumor cell invasive capacity, we first assessed
the effect on MMP2 expression, as a transcriptional readout of
tumor cell invasion. Treatment with the bAR agonist isoproterenol
increased MMP2 expression in scramble control tumor cells (black
bars, Fig. 2a), consistent with previous findings that bAR signaling
regulates MMP expression (Yang et al., 2006), but the effect was
attenuated in b2AR knockdown cells (grey bars, Fig. 2a). Pharmaco-
logical blockade of b2AR signaling using the b2AR-selective antago-
nist ICI-118,551 abolished the effect of isoproterenol on MMP2
expression in scramble control cells, providing pharmacological
confirmation that MMP2 expression is sensitive to b2AR signaling
(Fig. 2a). Of note, ICI-118,551 further reduced MMP2 expression
in isoproterenol-treated b2AR-deficient cells to baseline levels
(Fig. 2a), indicating that the incomplete knockdown of b2AR
(Fig. 1a) may be responsible for the residual MMP2 expression
observed in isoproterenol-treated knockdown cell lines (Fig. 2a).
To examine if b2AR knockdown also affected tumor cell mor-
phology, we used high-content screening to investigate the effect
of b2AR knockdown on MDA-MB-231HM cell morphology. Treat-
ment of scramble control cells with the bAR agonist isoproterenol
(vs. vehicle) in vitro, steadily increased the proportion of
mesenchymal-like cells over 3 days of treatment (black line,
Fig. 2b). In contrast, b2AR knockdown attenuated the effect of iso-
proterenol on mesenchymal morphology at day 3 (p < 0.001 for
shADRB2a, p < 0.05 for shADRB2b; grey lines, Fig. 2b and c). Addi-
tionally, pharmacological blockade of b2AR signaling using the
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proterenol on mesenchymal morphology in scramble control cells
(Supplementary Fig. 2a and b), pharmacologically confirming a role
for b2AR in tumor cell mesenchymal morphology.
Morphological transition from epithelial-like to amesenchymal-
like phenotype has been linked with increased tumor cell invasive-ness. To examine whether b2AR knockdown also impaired the func-
tional invasiveness of tumor cells, we treated MDA-MB-231HM cells
with the non-selective bAR agonist isoproterenol and examined
tumor cell invasion through a basement membrane using a tran-
swell invasion assay. Isoproterenol increased invasion in scramble
control cells by 30-fold (p < 0.05) (Fig. 2d). However, this effect of
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matrix degradation (grey patches of degradation on red-fluorescent gelatin), and (iv) merged image with inset panel showing active invadopodia that have degraded matrix.
Scale bar: 10 lm. (d) Quantification of invadopodia per cell in MCF7-WT cells and MC7-b2AR cells treated with vehicle, isoproterenol (non-selective bAR agonist, ISO, 0.5 lM)
or formoterol (b2AR-selective agonist, FORM, 0.5 lM) (n > 80 cells per condition). Data represent mean ± standard error. ⁄p < 0.05 and ⁄⁄⁄p < 0.001 by (a and b) unpaired t-tests
or (d) one-way ANOVA with post hoc Tukey’s planned comparison tests. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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(Fig. 2d), confirming that b2AR signaling in MDA-MB-231HM tumor
cells drives invasion. Collectively, these findings confirm that
genetic knockdown of b2AR modulates the tumor cell invasive phe-
notype in a way that replicates pharmacological b2AR blockade
(Creed et al., 2015; Pon et al., 2016).
MMPs are localized at subcellular structures called invadopodia
that regulate invasion of tumor cells (Murphy and Courtneidge,
2011). We found previously that b2AR regulation of invasion is
mediated by formation of invadopodia (Creed et al., 2015). To inde-
pendently validate the findings that genetic modulation of b2AR
affects tumor cell invasion, we overexpressed b2AR in MCF-7 breast
cancer cells which have low endogenous levels of b2AR, compared
to MDA-MB-231HM cells (Fig. 3a), and investigated the effect on
formation of invadopodia. MCF-7 cells were transduced with a con-
struct encoding a b2AR-GFP fusion protein and b2AR overexpres-
sion was confirmed at both the transcript and protein level usingqRT-PCR and fluorescence microscopy, respectively (Fig. 3b and c).
Tumor cell invasive capacity was assessed by formation of invasive
invadopodia structures that degrade underlying extracellular
matrix (Fig. 3c). Treatment with the b2AR-selective agonist for-
moterol or the non-selective agonist isoproterenol induced forma-
tion of invadopodia in cells that overexpressed b2AR, but not in
wildtype MCF-7 cells (Fig. 3d). Collectively, these in vitro findings
confirm that genetically modulating b2AR by either over-
expression or knockdown, affects isoproterenol-induced tumor cell
invasiveness, as demonstrated by transcriptional, morphological
and functional readouts (Figs. 2 and 3).
3.3. b2AR-driven tumor cell invasion contributes to stress-enhanced
metastasis in vivo
Having established that knockdown of b2AR in MDA-MB-231HM
cells limits bAR-regulated invasion in vitro (Fig. 2d) without
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down of b2AR in tumor cells also modulates the effect of stress on
metastatic dissemination from a primary tumor in vivo. In the com-
plex environment of the tumor, many stromal cell populations can
also respond to b2AR signaling, which plausibly may offset the
effect of b2AR-knockdown in tumor cells on metastasis. To model
breast cancer, scramble control tumor cells or b2AR knockdown
tumor cells were injected into the mammary fat pad of mice andbioluminescence imaging was used to non-invasively quantify
the onset and kinetics of metastasis to distant organs (Fig. 4a). Lon-
gitudinal analysis of spontaneous dissemination of metastatic
tumor cells from the primary tumor found that under baseline
(non-stress) conditions, knockdown of b2AR had no effect on
metastasis (Fig. 4a solid lines, and b). By day 28 of tumor progres-
sion, in mice with tumors derived from scramble control tumor
cells, chronic restraint stress increased metastasis by 10-fold,
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ous findings (Lamkin et al., 2015; Le et al., 2016; Sloan et al., 2010).
This overall increase in metastasis occurred as a consequence of a
daily 9.9% ± 0.77% increase in metastatic burden for the duration of
the experiment (Fig. 4c). Significantly, knockdown of ADRB2 in
tumor cells reduced this cumulative effect of stress on metastasis,
with mice bearing shADRB2a or shADRB2b tumors displaying a
reduction in stress-enhanced metastasis by 61.41% ± 12.25%
(p < 0.001) and 85.86% ± 13.30% (p < 0.001) respectively, compared
to mice with scramble control tumors (Fig. 4a–c).
To evaluate the effect of b2AR knockdown on tumor burden in
metastatic target organs, we used ex vivo bioluminescence imaging
to quantify metastatic tumor cells that had spread from the pri-
mary mammary tumor to lymph node and lung. Ex vivo analysis
confirmed that b2AR knockdown in MDA-MB-231HM tumor cells
blocked stress from increasing metastasis to both lymph node
and lung (p = 0.001, versus scramble control tumor cells)
(Fig. 4d and e).
The rate of primary tumor growth is highly prognostic for the
extent of tumor cell spread (Weigelt et al., 2005). Therefore, the
effects of b2AR signaling on metastasis may have occurred sec-
ondary to the effects on the primary tumor. In fact, assessment
of primary tumor mass on day 28 of tumor growth revealed that
stress produced a small, but significant, increase in primary tumorgrowth regardless of the b2AR status of tumors (p < 0.05; Fig. 5a).
We used regression analysis to evaluate the relationship between
the effect of stress on primary tumor growth rate and the effect
of stress on metastasis. Interestingly, the effect of stress on the pri-
mary tumor did not predict the effect of stress on metastasis in
control tumor cells with intact b2AR signaling (Fig. 5b). However,
knockdown of b2AR resulted in the expected positive correlation
between primary tumor growth rate and trajectory of metastatic
burden (Fig. 5c and d). Therefore, when b2AR is present on tumor
cells, stress drives metastasis independently of primary tumor
growth. Collectively, these findings demonstrate that even in the
complex tumor microenvironment where multiple cell populations
may respond to bAR signaling, b2AR-driven tumor cell invasion sig-
nificantly contributes to the effects of stress on accelerating metas-
tasis. Furthermore, these findings demonstrate the feasibility of
targeting b2AR-driven tumor cell invasion to inhibit the adverse
effects of stress on breast cancer metastasis.
4. Discussion
Despite major advances in cancer treatment, metastasis
remains a significant clinical challenge in the breast cancer clinic.
We and others have shown that chronic stress acts through bAR
signaling to drive metastasis (Kim-Fuchs et al., 2014; Le et al.,
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et al., 2015), and our previous in vitro findings have demonstrated
that b2AR signaling in cancer cells enhances invadopodia formation
and promotes tumor cell invasion in vitro (Creed et al., 2015; Pon
et al., 2016). However, the contribution of direct activation of
b2AR signaling in tumor cells (rather than through effects on the
tumor stroma) to metastatic dissemination from a primary tumor
is unclear. Here, we extend our understanding by showing that
b2AR signaling in human MDA-MB-231HM breast cancer cells con-
tributes to the deleterious effects of stress on metastatic dissemi-
nation from the complex microenvironment of a primary
mammary tumor. We found that silencing b2AR expression in
MDA-MB-231HM breast cancer cells blocked the effect of stress
on metastasis in vivo, which identifies tumor cells as an additional
in vivo target of stress-induced bAR signaling. These results expand
on earlier findings that demonstrated a role for stromal cells in the
tumor microenvironment in the adverse effects of stress on metas-
tasis, and suggests that bAR signaling in both tumor cells and stro-
mal cells contributes to the effect of stress on metastasis. This
raises the possibility that inhibiting stress signaling to either tumor
cells (as shown here) or to the tumor stroma (Le et al., 2016; Sloan
et al., 2010) may be sufficient to modulate metastasis.
Invasion is one of the critical steps along the metastatic cascade
that determines successful metastatic outgrowth. Notably,
incomplete knockdown of b2AR in MDA-MB-231HM tumor cells
(Fig. 1a) was sufficient to diminish stress-enhanced metastasis
(Fig. 4a and c), suggesting that even partial modulation of tumor
cell b2AR may be sufficient to slow breast cancer progression. We
also showed that the effects of stress-induced tumor b2AR signal-
ing on metastasis was independent of the effect on primary tumor
size (Fig. 5b–d). These results extend our previous findings that
pharmacological modulation of tumor cell b2AR regulates tumor
cell invasion in vitro (Creed et al., 2015; Pon et al., 2016), by show-
ing that b2AR signaling in tumor cells also plays a key role in driv-
ing metastasis in vivo.
It is possible that b2AR signaling may regulate an epithelial-to-
mesenchymal transition in tumor cells to increase metastatic inva-
sion and dissemination. Here, we observed that isoproterenol
treatment shifted MDA-MB-231HM cells towards a mesenchymal
morphology (Fig 2a), an effect that was attenuated by b2AR knock-
down. It will be important to characterize if b2AR agonism induces
similar behavior in other tumor cell lines and in vivo. Notably, sev-
eral recent in vitro studies suggest that bAR signaling induces an
epithelial-mesenchymal transition in gastric, colon and lung can-
cer cell lines (Lu et al., 2015; Shan et al., 2014; Zhang et al.,
2016). To better understand bAR regulation of epithelial-
mesenchymal transition it will be necessary to clarify the molecu-
lar mechanisms. While we found no evidence that bAR signaling
regulates expression of the mesenchymal marker vimentin in
MDA-MB-231HM breast cancer cells (data not shown), it will be
important to evaluate other molecules that are known to influence
epithelial-mesenchymal transition, including SNAIL and TWIST1.
Such studies should control for catecholamine-induced auto-
oxidation, which may also induce morphological changes.
While the in vivo findings described here are limited to the con-
tribution of tumor cell b2AR in metastatic dissemination in the
MDA-MB-231HM model of breast cancer, findings that stress also
increases metastasis in models of ovarian cancer (Thaker et al.,
2006), pancreatic cancer (Kim-Fuchs et al., 2014), and colorectal
cancer (Liu et al., 2015; Zhao et al., 2015), suggest that it will be
important to examine the role of tumor cell b2AR in metastatic dis-
semination of other tumor types. Additionally, while these results
highlight bAR-regulated tumor cell invasion as a significant con-
tributor to cancer progression, they do not exclude a role for bAR
signaling to stromal cells in the adverse effects of stress on metas-
tasis (Le et al., 2016; Sloan et al., 2010; Thaker et al., 2006). It islikely that the beneficial effects of bAR-targeted therapies (e.g., b-
blockers) on slowing metastasis are due to effects on both tumor
cells and stromal cells. Myeloid cells are sensitive to bAR signaling
(Le et al., 2016; Powell et al., 2013), which leads to their accumu-
lation in primary tumors where they remodel blood and lymphatic
vasculature to provide additional routes for tumor cell dissemina-
tion (Le et al., 2016; Sloan et al., 2010; Thaker et al., 2006). To fully
characterize the interactions between tumor cells and stromal cells
that mediate the effects of stress on metastasis, it will be valuable
to use additional strategies including ADRB2 knockout mice and
cell-specific ADRB2 deletion mutants to probe the contributions
of various cell types in the tumor microenvironment to stress-
induced cancer progression.
There are three subtypes of bAR that are expressed on both
stroma cells and tumor cells (Badino et al., 1996; Du et al., 2014;
Reeder et al., 2015; Vandewalle et al., 1990). While b2AR is the only
functional bAR subtype in MDA-MB-231HM cells (Creed et al., 2015;
Pon et al., 2016), other cancer cells have been shown to express
b1AR and b3AR subtypes (Dal Monte et al., 2013; Kim-Fuchs
et al., 2014; Magnon et al., 2013). However, the role of these recep-
tor subtypes in cancer progression is only starting to be elucidated
(Magnon et al., 2013). As the use of b-blockers to slowmetastasis is
clinically translated, it will be important to investigate the role of
other bAR subtypes in cancer progression. Second generation b-
blockers were developed for increased cardio-specificity by
increasing their selectivity for b1ARs, and are now more commonly
used than older generation non-selective b-blockers (Salpeter,
2003). Our findings that b2ARs on MDA-MB-231HM tumor cells also
contribute to metastasis suggest that some breast cancers may be
more effectively targeted with antagonists that also inhibit b2ARs
(e.g., propranolol). This is supported by a recent retrospective epi-
demiological study that found the use of non-selective b-blockers
that target both b1AR and b2AR, but not b1AR-selective blockers,
was associated with improved cancer outcome (Barron et al.,
2011). These findings provide insights into the contribution of
tumor cell b2AR signaling in stress-enhanced cancer progression
and further support the use of b-blockers to modulate breast
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